NextCure/$NXTC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NextCure
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Ticker
$NXTC
Sector
Primary listing
Employees
40
Headquarters
Website
NextCure Metrics
BasicAdvanced
$36M
-
-$19.65
1.55
-
Price and volume
Market cap
$36M
Beta
1.55
52-week high
$15.74
52-week low
$4.60
Average daily volume
38K
Financial strength
Current ratio
4.14
Quick ratio
3.967
Long term debt to equity
11.871
Total debt to equity
14.747
Profitability
EBITDA (TTM)
-55.431
Management effectiveness
Return on assets (TTM)
-54.96%
Return on equity (TTM)
-111.23%
Valuation
Price to book
1.01
Price to tangible book (TTM)
1.01
Price to free cash flow (TTM)
-0.578
Free cash flow yield (TTM)
-173.16%
Free cash flow per share (TTM)
-17.454
Growth
Earnings per share change (TTM)
-17.74%
3-year earnings per share growth (CAGR)
-15.29%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NextCure stock?
NextCure (NXTC) has a market cap of $36M as of March 20, 2026.
What is the P/E ratio for NextCure stock?
The price to earnings (P/E) ratio for NextCure (NXTC) stock is 0 as of March 20, 2026.
Does NextCure stock pay dividends?
No, NextCure (NXTC) stock does not pay dividends to its shareholders as of March 20, 2026.
When is the next NextCure dividend payment date?
NextCure (NXTC) stock does not pay dividends to its shareholders.
What is the beta indicator for NextCure?
NextCure (NXTC) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.